ライフサイエンスコーパス: hypothermia

1 odds ratio (with an odds ratio <1.0 favoring hypothermia).

2 -alpha hyperproduction and attenuates septic hypothermia.

3 istration in patients undergoing therapeutic hypothermia.

4 sed to manage overt shivering in therapeutic hypothermia.

5 Exposure: Induction of therapeutic hypothermia.

6 blockade in patients undergoing therapeutic hypothermia.

7 lems including QTc interval prolongation and hypothermia.

8 ilitates intra-cardiopulmonary resuscitation hypothermia.

9 induced conditioned taste aversion (CTA) and hypothermia.

10 ary resuscitation and the use of therapeutic hypothermia.

11 l and neurological benefit with mild induced hypothermia.

12 We conclude that TRPA1 mediates APAP evoked hypothermia.

13 fter the interim analysis showed efficacy of hypothermia.

14 be at greater risk of suffering harm due to hypothermia.

15 itivity and specificity for the detection of hypothermia.

16 enhanced the neuroprotective effects of mild hypothermia.

17 food allergy symptoms including diarrhea and hypothermia.

18 heightened sensitivity to MA-induced CTA and hypothermia.

19 by dihydrocapsaicin (DHC) produces reliable hypothermia.

20 .2 degrees C with zero incidence of systemic hypothermia.

21 rface area of the bowel may facilitate rapid hypothermia.

22 rest, who were treated with mild therapeutic hypothermia.

23 ecede the reduction in VO2 that brings about hypothermia.

24 ac arrest survivors treated with therapeutic hypothermia.

25 -hospital cardiac arrest receive therapeutic hypothermia.

26 d 72 hours in cases treated with therapeutic hypothermia.

27 stant to tumor necrosis factor (TNF)-induced hypothermia.

28 ysregulation of the inflammatory response to hypothermia.

29 patients (77%) were treated with therapeutic hypothermia.

30 MC-specific Munc13-4 KO mice developed less hypothermia.

31 hysiological effects such as hypotension and hypothermia.

32 of block in patients undergoing therapeutic hypothermia.

33 l for a full reversibility of the effects of hypothermia.

34 arrest (6.0%) were treated with therapeutic hypothermia; 1524 of these patients (mean [SD] age, 61.6

35 ar-old woman experienced profound accidental hypothermia (16.9 degrees C) in a mountainous region of

36 ypotension (276 of 491 policies [56.2%]) and hypothermia (181 of 228 policies [79.4%]), specifying al

37 egrees C to 0.43 degrees C for children) and hypothermia (-2.07 degrees C to 1.90 degrees C for adult

38 hermia: -28% +/- 3% and normothermia to mild hypothermia: -20% +/- 5%) was of comparable effect size

39 +/- 4%, normothermia: -27% +/- 6%, and mild hypothermia: -27% +/- 9%).

40 Likewise, therapeutic hypothermia (30 degrees C) inhibited Drp1-S637 dephospho

41 For more than a decade, mild induced hypothermia (32 degrees C-34 degrees C) has been standar

42 who were receiving mechanical ventilation to hypothermia (32 to 34 degrees C for 24 hours) in additio

43 agement) to standard care (control group) or hypothermia (32 to 35 degrees C) plus standard care.

44 Hypothermia (32-34 degrees C) can mitigate ischemic brai

45 ntional complications were more frequent for hypothermia (32.9% vs 9.1%; P < .001), delayed extubatio

46 (40% end-tidal concentration) combined with hypothermia (33 degrees C) for 24 h (n = 55; xenon group

47 o receive either inhaled xenon combined with hypothermia (33 degrees C) for 24 hours (n = 55 in the x

48 We combined hypothermia (33-35 degrees C for 1 h) with phenothiazine

49 C), normothermia (38.0 degrees C), and mild hypothermia (33.0 degrees C) on left ventricular contrac

50 luded perioperative settings without induced hypothermia (60 of 77 comparisons), perioperative settin

51 risons), perioperative settings with induced hypothermia (8 of 77), and induced hypothermia without a

52 l model of acute ischemic stroke by inducing hypothermia, a condition shown by itself to reduce the t

53 Patients randomized to hypothermia achieved a core body temperature of 34.7 deg

54 In this trial, induced hypothermia added to standard care was not associated wi

55 nsplant, external defibrillation/therapeutic hypothermia, advances in surgical myectomy, and alcohol

56 lic phase of cardiac arrest with therapeutic hypothermia, agents to treat or prevent reperfusion inju

57 mL at normothermia, and 41 +/- 3 mL at mild hypothermia; all p < 0.05).

58 enon combined with hypothermia compared with hypothermia alone resulted in less white matter damage a

59 triatum significantly (P < 0.01) faster than hypothermia alone, accompanied by more obvious (P < 0.01

60 matose survivors of OHCA, in comparison with hypothermia alone, inhaled xenon combined with hypotherm

61 vealed no association between intraoperative hypothermia and 30-day SSI (odds ratio, 1.17; 95% CI, 0.

62 ht percent of patients underwent therapeutic hypothermia and 471 (18%) exhibited myoclonus.

63 itory stimuli in 94 comatose patients, under hypothermia and after re-warming to normal temperature.

64 t, a TRPA1 antagonist inhibited APAP induced hypothermia and APAP was without effect on body temperat

65 tive agents offer promise when combined with hypothermia and are entering clinical trials.

66 ge cohort of patients undergoing therapeutic hypothermia and at investigating its added value on exis

67 urvival (>50%) of wild-type mice and reduced hypothermia and bacterial titers compared with vehicle-t

68 y tended to improve visceral organ function, hypothermia and combi treatment had no beneficial effect

69 Median door-to-balloon times in the hypothermia and control groups were 62 [51-81] and 47 [3

70 rred in 6 (21.4%) and 0 (0%) patients in the hypothermia and control groups, respectively (P=0.01), i

71 .2% [15.1-20.6] and 16.1% [10.0-22.2] in the hypothermia and control groups, respectively (P=0.54).

72 Neutralizing anti-IL-12 antibodies prevented hypothermia and death, demonstrating that endogenous GC-

73 rs improved the severity of shock, including hypothermia and decreased circulating IL-27p28.

74 duced peritonitis, cold exposure potentiated hypothermia and decreased survival (10 vs. 50%; P < 0.05

75 Both hypothermia and drinking during stimulation occurred in

76 VH) and passive systemic anaphylaxis-induced hypothermia and edema.

77 y phenotypes of hypothermia, suggesting that hypothermia and HSP90 inhibition may regulate these proc

78 sted the hypothesis whether mild therapeutic hypothermia and hyperoxia would attenuate postshock hype

79 diated systemic anaphylaxis, as indicated by hypothermia and increases in plasma tryptase levels.

80 Anaphylaxis severity was evaluated based on hypothermia and mortality.

81 Depletion of neutrophils protected against hypothermia and mortality.

82 leads to exacerbation of LPS-induced septic hypothermia and neutrophil influx.

83 s were 33.0 degrees C and 36.8 degrees C for hypothermia and normothermia groups.

84 ased energy expenditure and are resistant to hypothermia and obesity.

85 ostresuscitation care, including therapeutic hypothermia and percutaneous coronary intervention, bene

86 Therapeutic hypothermia and pharmacological sedation may influence o

87 patients undergoing robotic KT with regional hypothermia and report its safety and efficacy.

88 Low-dose CP55,940 also produced hypothermia and rimonabant-precipitated withdrawal in WT

89 evaluate the association between therapeutic hypothermia and survival after in-hospital cardiac arres

90 Hypothermia and systemic supportive care form the corner

91 suggests an association between therapeutic hypothermia and the risk of pneumonia and sepsis, wherea

92 The duration of hypothermia and the warming temperature seem to be criti

93 al energy as heat to protect animals against hypothermia and to counteract metabolic disease.

94 -infected mice exhibited neurological signs, hypothermia, and behavioral alterations characteristic o

95 lowed by urinary shedding, body weight loss, hypothermia, and colonization of the kidney by live spir

96 apitulated the cardiac rhythm abnormalities, hypothermia, and early death seen in RTT male mice.

97 iomarkers, current systemic supportive care, hypothermia, and emerging therapies for HIE and were rev

98 mammals as a natural defense system against hypothermia, and its activation to a state of increased

99 KO mice showed improved survival, attenuated hypothermia, and less proinflammatory cytokine productio

100 y elevated inflammatory cytokine production, hypothermia, and mortality.

101 bited strong CNS side effects, in catalepsy, hypothermia, and motor incoordination assays.

102 factors, including anesthesia, transfusions, hypothermia, and postoperative complications, as probabl

103 of cooling, target temperature, duration of hypothermia, and rewarming protocols were extracted.

104 s chronic pain, susceptibility to infection, hypothermia, and some cancers.

105 Cooling and hypothermia are profoundly neuroprotective, mediated, at

106 Hypothermia as a first line measure to reduce intracrani

107 sing efforts have focused on pharmacological hypothermia as a treatment option for stroke.

108 Mild hypothermia, as compared with normothermia, in organ don

109 ived in-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia,

110 out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia,

111 te macrophage colony-stimulating factor) and hypothermia at 18 hours.

112 2014, and either treated or not treated with hypothermia at 355 US hospitals were identified.

113 ly reported that inhaled xenon combined with hypothermia attenuates brain white matter injury in coma

114 symptom onset were randomized to peritoneal hypothermia before and for 3 hours after percutaneous co

115 either by boosting endogenous levels through hypothermia before the loss of the RBM3 response or by l

116 Neuromuscular blockade alone does not cause hypothermia but allowed acute respiratory distress syndr

117 Bradycardia is frequent during therapeutic hypothermia, but its impact on outcome remains unclear.

118 Importantly, a single 8 hour treatment of hypothermia by DHC after stroke provided long-term impro

119 Interestingly, hypothermia by DHC also significantly reduced secondary

120 we investigate the effects of TRPV1-mediated hypothermia by DHC on long-term ischemic stroke injury a

121 Hyperoxia and hypothermia can attenuate tissue hypoxia due to increase

122 In patients with traumatic brain injury, hypothermia can reduce intracranial hypertension.

123 and confounded by the choice of anesthesia, hypothermia, cardioplegia, and traumatic myocardial inju

124 tolerance, and cannabimimetic effects (e.g., hypothermia, catalepsy, CB1-dependent withdrawal signs)

125 mimetic activity, including antinociception, hypothermia, catalepsy, locomotor activity, and in the d

126 cardiac arrest, inhaled xenon combined with hypothermia compared with hypothermia alone resulted in

127 and sedative requirements (p < 0.001) during hypothermia compared with the 57 subjects discharged wit

128 -hospital cardiac arrest, use of therapeutic hypothermia compared with usual care was associated with

129 exhibit insensitivity to MA-induced CTA and hypothermia, compared with Taar1 wild-type mice.

130 lass of telomerase modulators in response to hypothermia conditions.

131 to withdraw therapy because of hyperthermia, hypothermia, dehydration, or sunburn.

132 Of the 445 patients with sepsis included, hypothermia developed in 64 patients (14.4%) (defined as

133 an preoptic area neurons produced a profound hypothermia due to cutaneous vasodilatation.

134 armacological activation of IGF-1R prevented hypothermia during calorie restriction.

135 have suggested that induction of therapeutic hypothermia during cardiopulmonary resuscitation (CPR) m

136 patients were assigned to either therapeutic hypothermia during CPR (618 patients) or standard prehos

137 technique for induction of mild therapeutic hypothermia during CPR is a rapid infusion of large-volu

138 l 10.2% of patients allocated to therapeutic hypothermia during CPR were alive at hospital discharge

139 the 13-lined ground squirrel, endure severe hypothermia during torpor followed by periodic rewarming

140 group, stage 2 treatments were added only if hypothermia failed to control intracranial pressure.

141 REW, which is akin to the in vivo changes of hypothermia followed by REW observed during IBA.

142 g agents for patients undergoing therapeutic hypothermia following cardiac arrest.

143 Treatment with mild therapeutic hypothermia for 24 hours followed by passive rewarming t

144 Hypothermia for 72 hours at 33.5 degrees C for neonatal

145 ising novel therapy, after the initiation of hypothermia for birth asphyxia would result in further i

146 ical trial to assess efficacy of therapeutic hypothermia for in-hospital cardiac arrest.

147 ttle, although limited examples (eg, induced hypothermia for out-of-hospital ventricular fibrillation

148 79 recipients of kidneys from donors in the hypothermia group (28%) and in 112 recipients of kidneys

149 0 organ donors had been enrolled (180 in the hypothermia group and 190 in the normothermia group).

150 y transplant (285 kidneys from donors in the hypothermia group and 287 kidneys from donors in the nor

151 very) occurred in 26% of the patients in the hypothermia group and in 37% of the patients in the cont

152 occurred in 67 of 138 patients (49%) in the hypothermia group and in 56 of 130 (43%) in the control

153 ons of children who died were similar in the hypothermia group and the control group (29% and 30%, re

154 ifference in the primary outcome between the hypothermia group and the normothermia group (20% vs. 12

155 ome did not differ significantly between the hypothermia group and the normothermia group (36% [48 of

156 val did not differ significantly between the hypothermia group and the normothermia group (49% [81 of

157 pilepticus on the first day was lower in the hypothermia group than in the control group (11% vs. 22%

158 More children in the hypothermia group than in the control group survived wit

159 Adverse events were more frequent in the hypothermia group than in the control group.

160 ; P=0.04), indicating a worse outcome in the hypothermia group than in the control group.

161 A total of 75 of 145 children (52%) in the hypothermia group versus 52 of 132 (39%) in the control

162 and 1-year survival was similar (38% in the hypothermia group vs. 29% in the normothermia group; rel

163 WIN55, 212-2 hypothermia group was associated with significantly impr

164 s 12 months after injury; in the therapeutic hypothermia group, four (17%) had a bad outcome (pediatr

165 In the hypothermia group, stage 2 treatments were added only if

166 Except for the WIN55, 212-2 hypothermia group, the body temperature in the other two

167 trol group and in 44% of the patients in the hypothermia group.

168 of 364 neonates were randomly assigned to 4 hypothermia groups: 33.5 degrees C for 72 hours (n = 95)

169 is now better understood, and treatment with hypothermia has become the foundation of therapy.

170 Therapeutic hypothermia has been used to attenuate the effects of tr

171 Recently, the neuroprotective therapy of hypothermia has emerged as the standard of care, and oth

172 Physical hypothermia has long been considered a promising neuropr

173 Therapeutic hypothermia (HT) is standard care for moderate and sever

174 otected NTHi-infected mice from weight loss, hypothermia, hypoxemia, and respiratory compromise.

175 uirements early in the course of therapeutic hypothermia improve the identification of patients who w

176 rt conducting a randomized clinical trial of hypothermia in acute respiratory distress syndrome and t

177 roidal anti-inflammatory drugs, APAP elicits hypothermia in addition to its antipyretic effect.

178 t also induced transient and estrus-specific hypothermia in animals fed ad libitum.

179 Early therapeutic hypothermia in children with severe traumatic brain inju

180 the dorsomedial hypothalamus (DMH) promoted hypothermia in cold-exposed restrained rats, but attenua

181 toneal cavity to rapidly induce and maintain hypothermia in comatose patients after cardiac arrest an

182 The effect that targeted mild hypothermia in organ donors before organ recovery has on

183 of performing a randomized clinical trial of hypothermia in patients with acute respiratory distress

184 cold-exposed restrained rats, but attenuated hypothermia in rats challenged with a high dose of bacte

185 Therapeutic hypothermia in the ICU requires mechanical ventilation a

186 ituted Sash) were given LPS to induce septic hypothermia in the presence or absence of indicated inhi

187 Titrated Hypothermia in the range 32-35 degrees C as the primary

188 exia, administration of APAP evoked a marked hypothermia in wildtype and Trpv1(-/-) mice, but only re

189 lls are indispensable for LPS-induced septic hypothermia, in which TNF-alpha plays an essential role

190 Complications of perioperative hypothermia include coagulopathy and increased transfusi

191 We discuss complications of hypothermia including shivering, electrolyte abnormaliti

192 o normothermia and from normothermia to mild hypothermia increased left ventricular contractility to

193 genic pathway but also led, unexpectedly, to hypothermia, increased blood acetaldehyde concentrations

194 Hypothermia increases both the prevalence and magnitude

195 ned the feasibility, safety, and efficacy of hypothermia induced by an automated peritoneal lavage sy

196 Hypothermia induced by cold saline and endovascular cool

197 rmic life support (control group, n = 12) or hypothermia induced by either 30 minutes of total liquid

198 dine, cilostazol, and milrinone suppress the hypothermia-induced VT/VF by reversing the repolarizatio

199 Surprisingly, our data show that hypothermia-inducing LepRb(POA) neurons are glutamatergi

200 Despite better hypothermia induction and maintenance, endovascular cool

201 Hypothermia initiated at 3.5 hours after stroke signific

202 nfants with hypoxic-ischemic encephalopathy, hypothermia initiated at 6 to 24 hours after birth compa

203 Hypothermia initiated at 6 to 24 hours after birth may h

204 To estimate the probability that hypothermia initiated at 6 to 24 hours after birth reduc

205 Hypothermia initiated at less than 6 hours after birth r

206 We tested the hypothesis that development of hypothermia instead of fever in endotoxic shock is conse

207 ncluding incidence of diarrhea, incidence of hypothermia, intestinal TH2 immune response, and serum O

208 Unintentional intraoperative hypothermia is a well-described risk factor for surgical

209 Early introduction of mild therapeutic hypothermia is an established treatment goal.

210 Hypothermia is associated with higher mortality and an i

211 These findings indicate that TRPV1-mediated hypothermia is effective in reducing both primary cortic

212 Peritoneal hypothermia is feasible and achieves rapid cooling with

213 Hypothermia is known to result in similar electrocardiog

214 Therapeutic hypothermia is likely a beneficial treatment following t

215 Therapeutic hypothermia is recommended for comatose adults after wit

216 Importance: Therapeutic hypothermia is used for patients following both out-of-h

217 Hypothermia leads to VT/VF in the setting of ER by exagg

218 However, the required degree of hypothermia, length of its use, and its timing are uncer

219 2 cells, mast cells, and eosinophils, shock (hypothermia), mast cell degranulation (increased serum m

220 with volatile anesthetics during therapeutic hypothermia may be a feasible short-acting option with p

221 Prior studies suggest hypothermia may be beneficial in acute respiratory distr

222 part of the postcardiac arrest syndrome, and hypothermia may pose additional impact on hemodynamics.

223 Systemic hypothermia may reduce infarct size if established befor

224 appropriate included pre- and intraoperative hypothermia (median temperature <34 degrees C), acidosis

225 ptogenetic excitation of WSNs triggers rapid hypothermia, mediated by reciprocal changes in heat prod

226 our patients were randomized at 7 centers to hypothermia (n=28) versus control (n=26).

227 re 34 degrees C), or "combi" (hyperoxia plus hypothermia) (n = 9 each).

228 the form of heat, thereby defending against hypothermia, obesity, and diabetes.

229 The benefit of hypothermia on functional outcome is unclear.

230 degrees C partially reverses the effects of hypothermia on monocyte function.

231 We evaluated the effect of induced hypothermia on neurologic outcomes in patients with conv

232 High-dose CP55,940 did not produce hypothermia or rimonabant-precipitated withdrawal in CB1

233 ate 3 key questions: (1) Should mild induced hypothermia (or some form of targeted temperature manage

234 eted temperature ranges: 34 to 35 degrees C (hypothermia) or 36.5 to 37.5 degrees C (normothermia).

235 erance, CB1-mediated cannabinoid withdrawal, hypothermia, or motor dysfunction.

236 ythms from the Penn Alliance for Therapeutic Hypothermia (PATH) registry between 2000 and 2013.

237 Hg after traumatic brain injury, therapeutic hypothermia plus standard care to reduce intracranial pr

238 Total Body hypothermia plus Xenon (TOBY-Xe) was a proof-of-concept,

239 We have previously shown that hypothermia prolongs the proinflammatory response wherea

240 ncephalopathy who have undergone therapeutic hypothermia, quantitative magnetic resonance measures in

241 Patients allocated to therapeutic hypothermia received a mean (SD) of 1193 (647) mL cold s

242 Hypothermia reduces intracranial hypertension in patient

243 bability of reduced death or disability with hypothermia relative to the noncooled group (adjusted po

244 Hypothermia results initially from an internal redistrib

245 ntervention in the perioperative and induced hypothermia settings.

246 Hypothermia shows promise for stroke neuroprotection, bu

247 a" (standard resuscitation, but FIO2, 1.0), "hypothermia" (standard resuscitation, but core temperatu

248 symptomatic and/or lethal coinfections, and hypothermia strongly correlated with mortality.

249 pothermia alone, inhaled xenon combined with hypothermia suggested a less severe myocardial injury as

250 tes the quiescence and latency phenotypes of hypothermia, suggesting that hypothermia and HSP90 inhib

251 thermoregulatory site that worked as a fever-hypothermia switch.

252 of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degrees C) or ther

253 of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degrees C) or ther

254 Therapeutic hypothermia (TH) attenuates reperfusion injury in comato

255 ensive meta-analysis to quantify benefits of hypothermia therapy for traumatic brain injuries in adul

256 alth burden for millions of infants, despite hypothermia therapy.

257 d care alone (control) or standard care with hypothermia to a rectal temperature of 33 to 34 degrees

258 The intervention group had therapeutic hypothermia to a temperature of 32-33 degrees C for 72 h

259 progression of auditory discrimination from hypothermia to normothermia has a high predictive value

260 Abrupt temperature shift from hypothermia to normothermia incurred on reperfusion of o

261 An increase in auditory discrimination from hypothermia to normothermia was observed for 33 out of 9

262 d on the change of decoding performance from hypothermia to normothermia.

263 eurological survival for the overall cohort (hypothermia-treated group, 17.0% [246 of 1443 patients];

264 ted group, 17.0% [246 of 1443 patients]; non-hypothermia-treated group, 20.5% [725 of 3529 patients];

265 were matched by propensity score to 3714 non-hypothermia-treated patients (mean [SD] age, 62.2 [17.5]

266 for 24 hours (n = 55 in the xenon group) or hypothermia treatment alone (n = 55 in the control group

267 degrees C) for 24 h (n = 55; xenon group) or hypothermia treatment alone (n = 55; control group).

268 Hypothermia treatment did not alter these relationships.

269 Prospective hypothermia treatment in eight acute respiratory distres

270 To our knowledge, hypothermia trials have not been performed in infants pr

271 al depletion of mitochondrial ROS results in hypothermia upon cold exposure, and inhibits UCP1-depend

272 cessfully underwent robotic KT with regional hypothermia using a modified intraoperative management p

273 ardiac arrest, induction of mild therapeutic hypothermia using a rapid infusion of large-volume, intr

274 Hypothermia was a significant independent predictor of p

275 Hypothermia was abolished in mice pre-treated with resin

276 Therapeutic hypothermia was also associated with lower rates of favo

277 in the present randomized trial, peritoneal hypothermia was associated with an increased rate of adv

278 Bradycardia during therapeutic hypothermia was associated with good neurologic outcome

279 After adjustment, therapeutic hypothermia was associated with lower in-hospital surviv

280 rge electrolytic DMH lesions on cold-induced hypothermia was due to suppressed thermogenesis.

281 y was independent of TRPV1 since APAP evoked hypothermia was identical in wildtype and Trpv1(-/-) mic

282 rees C) was significantly shorter and target hypothermia was more strictly maintained in the endovasc

283 The lacking efficacy of hypothermia was most likely due to more pronounced barri

284 -2.6]), whereas no difference in therapeutic hypothermia was noted.

285 Only when hypothermia was prevented by exposure to a warm environm

286 Hypothermia was successfully initiated in 96.3% of patie

287 arrest population treated with mild induced hypothermia, we found a 41% good outcome at hospital dis

288 Because LPS causes both fever and hypothermia, we originally thought that the DMH containe

289 IL-15 SA caused dose- and time-dependent hypothermia, weight loss, liver injury, and mortality.

290 ormothermic, those who underwent therapeutic hypothermia were associated with 18% reduction in mortal

291 continuously, and 4 possible definitions of hypothermia were explored, including temperature nadir,

292 tion sites showed that sites associated with hypothermia were more anteroventral than those associate

293 omy and sustained a period of intraoperative hypothermia were no more likely to develop an SSI than t

294 , and lead to more severe LPS-induced septic hypothermia when reconstituted into mast cell-deficient

295 g from hyperthermia to normothermia and mild hypothermia, whereas left ventricular contractility incr

296 and ultrarapid method to induce and maintain hypothermia, which appears feasible in cardiac arrest pa

297 By combining hypothermia with phenothiazines, we significantly enhanc

298 re observed by the pharmacologically induced hypothermia with WIN55, 212-2.

299 encephalopathy treated with mild therapeutic hypothermia within 24 hours after cardiac arrest.

300 h induced hypothermia (8 of 77), and induced hypothermia without anesthesia (9 of 77).